IHC Extended Panel (>10Markers)- Test
Short Name: IHC Extended Panel
Also known as: IHC Extended Panel, Immunohistochemistry Extended Panel, IHC Panel More Than 10 Markers, Extended IHC Staining Panel, Tumor Marker IHC Panel
IHC Extended Panel (>10Markers)- Test test available at DNA Labs India for ₹9,750. Uses Immunohistochemistry (IHC), Antibody-based Protein Detection, Microscopic Evaluation on Tissue / Paraffin Block samples. Results in Results are typically available within 5 working days from the date of sample receipt at the laboratory.. Free home collection in 300+ cities across India.
🩺 Medically Reviewed By
Dr Pasupathy Arumugam
Consultant Pathologist · Reg: 21521
Last reviewed: September 7, 2026
Overview
The IHC Extended Panel is performed to identify and characterize specific proteins expressed in tissue samples, aiding in the accurate diagnosis, classification, and grading of cancers and other diseases. It helps determine tumor origin, subtype, and biological behavior. The panel identifies hormone receptors such as estrogen receptor (ER) and progesterone receptor (PR), growth factor receptors like HER2/neu, proliferation markers such as Ki-67, and tumor suppressor proteins like p53. These markers are essential for predicting prognosis, selecting targeted therapies, monitoring treatment response, and detecting disease recurrence. The extended panel is especially useful when initial histopathological examination is inconclusive or when a comprehensive molecular profile is needed for treatment planning.
- Test Code
- 3062
- CPT Code
- 88342
- ICD Code
- Z12.4
- Price
- ₹9,750
- Sample Type
- Tissue / Paraffin Block
- Result Time
- Results are typically available within 5 working days from the date of sample receipt at the laboratory.
- Fasting Required
- No
- Method
- Immunohistochemistry (IHC), Antibody-based Protein Detection, Microscopic Evaluation
Sample Collection
A doctor's prescription is required for the IHC Extended Panel. The prescription is not applicable for surgery and pregnancy cases or individuals planning to travel abroad. Inform your physician about any medications or prior treatments that may affect tissue characteristics.
Method: Biopsy / Surgical Excision
Laboratory Analysis
The tissue sample is obtained through a biopsy (needle biopsy, incisional biopsy, or excisional biopsy) or surgical excision performed by a qualified surgeon or interventional specialist. The specimen is immediately placed in 10% neutral buffered formalin for proper fixation. If a paraffin block is already available from a previous procedure, it can be submitted directly.
Report Delivery
After collection, the tissue undergoes processing, embedding in paraffin, sectioning, and staining with multiple antibodies targeting the markers in the panel. The stained slides are examined by a qualified pathologist. Results are typically available within 5 days and can be accessed via the online portal, email, or WhatsApp.
Timeline: Results are typically available within 5 working days from the date of sample receipt at the laboratory.
Patient Instructions
About This Test
Who Should Get This Test
The IHC Extended Panel is performed to identify and characterize specific proteins expressed in tissue samples, aiding in the accurate diagnosis, classification, and grading of cancers and other diseases. It helps determine tumor origin, subtype, and biological behavior. The panel identifies hormone receptors such as estrogen receptor (ER) and progesterone receptor (PR), growth factor receptors like HER2/neu, proliferation markers such as Ki-67, and tumor suppressor proteins like p53. These markers are essential for predicting prognosis, selecting targeted therapies, monitoring treatment response, and detecting disease recurrence. The extended panel is especially useful when initial histopathological examination is inconclusive or when a comprehensive molecular profile is needed for treatment planning.
How to Prepare
- Obtain a valid doctor's prescription specifying the IHC Extended Panel
- Ensure the tissue specimen is placed in 10% neutral buffered formalin immediately after collection
- If submitting a paraffin block, ensure it is properly labeled with patient details
- Provide complete clinical history and provisional diagnosis for accurate interpretation
- Avoid contamination of the specimen with other tissues or fluids
- Transport the specimen at ambient temperature to the laboratory
Doctor's Notes
Reviewed by Dr Pasupathy Arumugam — MBBS, MD (Pathology) · Reg. No. 21521
"The IHC Extended Panel is an indispensable tool in modern oncology practice. By evaluating more than 10 protein markers simultaneously, it allows clinicians to accurately subtype tumors, predict prognosis, and select targeted therapies. For instance, ER, PR, and HER2 status in breast cancer directly determines whether a patient will benefit from hormonal therapy or trastuzumab-based regimens. I strongly recommend this panel for any newly diagnosed malignancy where comprehensive biomarker profiling is essential for treatment planning."
Last medically reviewed: September 7, 2026
Test Parameters & Specifications
Sample Stability
- Specimen received without proper fixation in 10% neutral buffered formalin
- Tissue specimen with extensive autolysis or necrosis rendering interpretation impossible
- Specimen without proper labeling or patient identification
- Paraffin block with no viable tissue remaining
- Specimen received without a valid doctor's prescription (where applicable)
Understanding Your Results
Luminal A breast cancer subtype. Generally associated with favorable prognosis and good response to hormonal therapy such as tamoxifen or aromatase inhibitors.
Luminal B breast cancer subtype. May benefit from combined hormonal therapy and HER2-targeted therapy such as trastuzumab.
HER2-enriched breast cancer subtype. Eligible for HER2-targeted therapies. Often more aggressive but responsive to trastuzumab-based regimens.
Triple-negative breast cancer. More aggressive subtype with limited targeted therapy options. Chemotherapy remains the mainstay of treatment. Immunotherapy may be considered in select cases.
Indicates high tumor proliferation rate. Associated with more aggressive behavior and may warrant more intensive treatment protocols.
Suggests TP53 gene mutation. Associated with aggressive tumor behavior and may indicate poorer prognosis depending on tumor type.
Helps classify lymphoid neoplasms. CD20 positivity indicates B-cell lineage; CD3 positivity indicates T-cell lineage. Essential for lymphoma subtyping.
Consult your oncologist or treating physician if your IHC Extended Panel results show abnormal marker expression, if markers indicate an aggressive tumor subtype, or if the results are discordant with clinical findings. Your doctor will correlate the IHC profile with imaging, clinical stage, and other laboratory results to formulate an appropriate treatment plan. If you have been diagnosed with cancer and have not undergone IHC testing, discuss with your oncologist whether this panel is appropriate for your case.
Limitations
- ⚠IHC results are semi-quantitative and subject to inter-observer variability
- ⚠The panel does not replace molecular genetic testing such as FISH or NGS for certain markers
- ⚠False positives or negatives may occur due to technical or biological factors
- ⚠Not all markers in the panel may be relevant for every tumor type
- ⚠Results must always be interpreted in conjunction with clinical history, morphology, and other diagnostic findings
- ⚠Turnaround time may be extended for cases requiring additional special stains or confirmatory tests
Risks & Considerations
- ●As this test is performed on an already collected tissue specimen, there are no direct risks to the patient from the IHC procedure itself
- ●The biopsy or surgical procedure used to obtain the tissue specimen carries standard procedural risks such as bleeding, infection, or discomfort at the collection site
- ●False positive or false negative results are possible, which may affect clinical decision-making
- ●Emotional impact of results; counseling and physician consultation are recommended
Interfering Factors
- ●Inadequate fixation of tissue specimen leading to antigen degradation
- ●Prolonged storage of paraffin-embedded blocks affecting antigen integrity
- ●Use of improper fixatives other than 10% neutral buffered formalin
- ●Tissue necrosis or extensive hemorrhage within the specimen
- ●Prior decalcification procedures that may damage certain antigens
- ●Technical variations in staining protocols across laboratories
Compare With Similar Tests
| Test | IHC Extended Panel (>10Markers)- | IHC Basic Panel | FISH (Fluorescence In Situ Hybridization) | Next-Generation Sequencing (NGS) | Histopathology (H&E Staining) |
|---|---|---|---|---|---|
| Comparison | IHC Extended Panel (>10Markers)- | The basic IHC panel typically includes fewer than 5 markers and is suitable for initial screening. The extended panel provides a more comprehensive analysis with more than 10 markers for detailed tumor characterization. | FISH detects gene amplification or rearrangement at the DNA level and is often used to confirm HER2 status when IHC results are equivocal (2+). IHC evaluates protein expression while FISH evaluates gene-level changes. | NGS provides comprehensive genomic profiling including mutations, fusions, and copy number alterations. While more expensive and time-consuming, NGS offers deeper molecular insights beyond protein expression detected by IHC. | Routine H&E staining provides morphological assessment of tissue architecture and cellular features. IHC extends this by identifying specific proteins that help classify and subtype tumors beyond what morphology alone can reveal. |
Frequently Asked Questions
What is the IHC Extended Panel (>10 Markers)?
What sample is required for the IHC Extended Panel?
How is the IHC Extended Panel different from a basic IHC panel?
What is the cost of the IHC Extended Panel at DNA Labs India?
How long does it take to get the results of the IHC Extended Panel?
Do I need a doctor's prescription for the IHC Extended Panel?
What types of cancer can the IHC Extended Panel help diagnose?
Is fasting required before the IHC Extended Panel test?
What does a positive or negative IHC result mean?
Can the IHC Extended Panel help determine the best treatment for cancer?
Is home sample collection available for the IHC Extended Panel?
What should I do if my IHC Extended Panel results are abnormal?
Related Tests
Reference Laboratory Services
We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.
Your Data Privacy
Your medical data is protected under Indian law.
✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.
✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.
Book Your Test
Enter your details and we'll connect you within 15 minutes.